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Abstract: Hepatocellular carcinoma (HCC) is frequently diagnosed in the setting of chronic 
liver disease and cirrhosis. The median survival after diagnosis is dismal. The treatment options 
that may offer cure are either resection or liver transplantation. Unfortunately most patients are 
not eligible for either treatment modality at diagnosis because of advanced stage and underlying 
liver dysfunction. Until recently, there was no effective systemic therapy for patients with 
advanced HCC. Sorafenib, an oral multikinase inhibitor of the vascular endothelial growth 
factor receptor, the platelet-derived growth factor receptor and Raf, has shown antitumor 
activity in patients with advanced HCC in phase III trials. Although objective response is not 
common, sorafenib promotes disease stabilization and improves overall survival. Sorafenib is 
well tolerated with a favorable toxicity profile. In this article we review the efficacy and safety 
data for sorafenib in patients with advanced HCC.
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Introduction
Hepatocellular carcinoma (HCC) comprises the third highest cause of cancer death 
worldwide.1 Surgical resection offers a cure; however most patients are ineligible 
for resection at the time of diagnosis because of tumor extent and underlying liver 
disease. Prognosis remains dismal in unresectable patients with a median survival of 
3 to 6 months after diagnosis.2 Liver transplantation in properly selected patients with 
unresectable tumors offers the potential for cure and the treatment of the underlying 
liver disease.
Conventional therapeutic options for advanced HCC are limited. HCC is 
resistant to cytotoxic chemotherapy due in part to the high rate of expression of drug 
resistance genes. A small percentage of patients with HCC benefit from cytotoxic 
therapy, and until recently no improved survival in this patient population had been 
demonstrated.
Sorafenib is an oral small molecule multikinase inhibitor with antiproliferative 
and antiangiogenic effects (Figure 1). It acts predominantly by inhibiting the 
activity of the serine/threonine kinases c-Raf and B-Raf and vascular endothelial 
growth factor receptors (VEGFR) 1, 2 and 3. Other targets include the mitogen-
activated protein kinases MEK and ERK; the platelet derived growth factor receptor 
(PDGFR); the cytokine receptor c-KIT; the receptor tyrosine kinases Flt-3 and RET; 
and the Janus kinase/signal transducer and activator of transcription (JAK/STAT) 
pathway.3 The Raf/MEK/ERK intracellular signaling pathway and the VEGFR and OncoTargets and Therapy 2009:2 262
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PDGFR extracellular receptors have been implicated in the 
pathogenesis of hepatocellular carcinoma, prompting the 
investigation of sorafenib in advanced HCC. In addition 
the hypervascularity of HCC suggests that strategies 
targeting angiogenesis may be worthwhile in controlling 
disease progression.4–7
Efficacy of sorafenib in patients 
with advanced hepatocellular 
carcinoma
Phase i and ii studies
The efficacy of sorafenib in HCC was initially suggested 
by a phase I trial of sorafenib in advanced refractory solid 
tumors8 in which one patient with HCC showed a partial 
response at 400 mg twice daily continuous sorafenib lasting 
more than 6 months. Three out of 6 patients with HCC in 
that study showed disease stabilization lasting for months. 
Another phase I trial9 evaluated the pharmacokinetics, 
safety, and efficacy of sorafenib in Japanese patients with 
HCC. Twenty-seven patients with unresectable HCC, Child-
Pugh status A (CPA) or B (CPB), were treated. Among the 
24 patients evaluable for tumor response, 1 patient (4%) 
achieved a partial response, 20 (83%) had stable disease, 
and 3 (13%) had progressive disease. The median time 
to progression was 4.9 months and the median overall 
survival was 15.6 months. Subsequently, a phase II trial of 
sorafenib in patients with advanced HCC was conducted.10 
One hundred and thirty patients with inoperable HCC and 
CPA or B were treated with sorafenib 400 mg twice daily. 
Three (2.2%) patients achieved partial response (PR), 
8 (5.8%) had a minor response, and 46 (33.6%) had stable 
disease for at least 16 weeks. Median time to progression 
(TTP) was 4.2 months, and median overall survival (OS) 
was 9.2 months. Despite a shorter course of therapy for 
patients with CPB (12.9 weeks) compared to CPA (24.9 
weeks), sorafenib discontinuation rates (CPA 31% vs CPB 
21%) and dose reduction (CPA 31% vs CPB 21%) were 
similar in both group. Median TTP for patients with CPA 
was 21 weeks compared to 13 week in CPB patients. Over-
all survival for patients with CPA and CPB was 41 weeks 
14 weeks respectively.11 Another phase II open label study 
of single-agent sorafenib was conducted in hepatitis 
B-endemic Asian population with HCC.12 Fifty-one patients 
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Figure 1 Sorafenib acts by inhibiting the activity of c-raf and B-raf; vascular endothelial growth factor receptors (veGFr); the mitogen-activated protein kinases MeK and 
erK; and platelet derived growth factor receptors (PDGFr).OncoTargets and Therapy 2009:2 263
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were enrolled. The overall median progression-free survival 
was 3 months and OS was 5 months. Response rate was 
modest, 8% of patients achieving PR and 18% had stable 
disease for at least 12 weeks. Patients without extrahepatic 
spread (EHS), particularly lung metastases, were more likely 
to benefit from the treatment.
Phase iii trials (Table 1)
SHArP study
On the basis of the above phase II studies, a double-blind, 
placebo-controlled phase III trial of sorafenib in advanced 
HCC was conducted (Sorafenib HCC Assessment Random-
ized Protocol Trial: SHARP trial).13 Six hundred and twenty 
patients with advanced HCC were randomized to receive 
either sorafenib 400 mg twice daily or placebo. Primary 
endpoints were OS and time to symptomatic progression 
(TTSP). Secondary endpoint was time to radiologic 
progression and safety. The study was stopped after the 
second planned interim analysis at which 321 deaths 
had occurred. Median OS was significantly longer in the 
sorafenib-treated patients (10.7 vs 7.9 months) as was 
median time to radiologic progression (5.5 vs 2.8 months). 
Time to symptomatic progression was similar in both 
groups (4.1 vs 4.9 months). Two percent of patients in 
the sorafenib arm had a partial response compared to 1% 
of patients in the placebo group. Based on these results 
sorafenib was approved in the United States and became the 
standard of care for patients with advanced HCC.
An exploratory subgroup analysis showed a survival 
benefit for sorafenib over placebo regardless of HCV status, 
ECOG performance status (PS), EHS/microscopic vascular 
invasion, and prior curative treatment.
Of the 602 patients enrolled in the SHARP study, 
178 patients were positive for hepatitis C virus infection 
(HCV), 93 patients in the sorafenib arm and 85 in the 
placebo arm. In the HVC positive subgroup the median 
overall survival was higher in the sorafenib group (14.0 vs 
7.9 months) as was median time to radiologic progression by 
independent review (7.6 vs 2.8 months). The disease control 
rate (DCR), defined as the percentage of patients who had 
a best-response rating of complete or partial response or 
stable disease that was maintained for at least 28 days 
after the first demonstration of that rating on independent 
radiologic review, was higher in the sorafenib group also 
(44 vs 31%).14
The influence of  PS on efficacy of sorafenib in the SHARP 
trial was reported. Out of 602 patients enrolled on the study, 
325 had ECOG PS 0 at baseline and 277 had PS 1–2. Among 
patients with ECOG PS 0, the median OS was higher in the 
sorafenib group (13.3 vs 8.8 months) as was the median time 
to progression (5.5 vs 2.9 months). Among patients with 
ECOG PS 1–2, the median OS (8.9 vs 5.6 months) and the 
median time to progression (3.5 vs 2.8) were also higher 
in the sorafenib group, indicating that sorafenib prolonged 
OS and TTP in patients with advanced HCC irrespective 
of ECOG PS.15
The effect of macroscopic vascular invasion (MVI) 
and/or EHS, on the efficacy of sorafenib in the SHARP 
study was also evaluated. In this subanalysis, 421/602 
patients had MVI and/or EHS. Patients with MVI 
and/or EHS treated with sorafenib had a higher OS 
(8.9 vs 6.7 months) and longer TTP (4.1 vs 2.7 months) 
than patients treated with placebo; similarly patients with-
out MVI and/or EHS had OS of 14.5 months in sorafenib-
treated patients versus 10.2 months in patients treated with 
placebo. TTP was longer in sorafenib-treated patients as 
well (9.6 vs 4.3 months).16
The effects of previous liver-directed treatment on 
survival in the SHARP trial population was analyzed; in 
this subanalysis, 158 patients (81 sorafenib, 77 placebo) 
underwent prior curative treatment and 176 patients 
Table 1 Patient characteristics and outcome in phase iii clinical 
trials of sorafenib versus placebo in advanced HCC
Variable SHARP Asia-Pacific
  Sorafenib Placebo Sorafenib Placebo
No of patients 299 303 150 76
Age (year) 64.9 66 51 52
HCv infection (%) 29 27 11 4
HBv infection (%) 19 18 70 77
Child-Pugh class
    A (%) 95 98 97.3 97.4
  B (%) 5 2 2.7 2.6
PS (%)
  0 54 54 25 27
  1 38 39 69 67
  2 8 7 5 5
Median OS (months) 10.7 7.9 6.5 4.2
Median TTP (months) 5.5 2.8 2.8 1.4
response rate (%) 2 1 3 1
  Complete response 0 0 0 0
  Partial response 2 1 3.3 1.3
  Stable disease 71 67 54 27
  DCr 43 32 35 16
Abbreviations: HCv,  hepatitis C virus; HBv,  hepatitis B virus; OS, overall survival; 
TTP,  time to progression; DCr, disease control rate; PS, performance status.OncoTargets and Therapy 2009:2 264
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(86 sorafenib, 90 placebo) underwent transarterial 
chemoembolization (TACE). Patients with prior liver-directed 
therapy treated with sorafenib had a higher OS (11.9 vs 
8.8 months) and longer TTP (5.5 vs 2.8 months) than placebo-
treated patients, similar to patients with prior TACE therapy 
who had an OS and TTP of 11.9 and 5.8 months respectively 
in sorafenib-treated patients compared to 9.9 and 4 months 
in patients treated with placebo.17
Asia-Pacific study
Another double-blind, placebo-controlled phase III trial 
was conducted to evaluate the efficacy of sorafenib in 
HCC patients in the Asia-Pacific region.18 Two hundred 
and seventy one patients from China, South Korea, and 
Taiwan with CPA liver function class, were randomly 
assigned to receive either oral sorafenib (400 mg) or 
placebo twice daily. There was no predefined primary 
endpoint. Overall survival, TTP, TTSP, DCR, and safety 
were assessed by intention to treat analysis. Median OS 
was 6.5 months in patients treated with sorafenib, compared 
to 4.2 months in those who received placebo. Median TTP 
was 2.8 and 1.4 months in the sorafenib and the placebo 
group, respectively. Of note the median age of patients 
in this study was lower than in the SHARP study and a 
the population of patients with hepatitis B virus (HBV) 
infection was larger.
Despite a shorter median survival in patients on placebo 
indicating a worse population than the SHARP study, 
a prespecified subgroup analysis showed a clinical benefit 
in all subgroups including patients with worse ECOG PS, 
vascular invasion, age 65 years, macroscopic vascular 
invasion or extrahepatic spread (or both), and HBV.
Sorafenib in combination 
with other therapy
Based on promising results from a phase I trial in patients 
with advanced hepatocellular carcinoma,19 a combination 
of sorafenib and doxorubicin was evaluated in a random-
ized phase II trial. Ninety-six patients with advanced HCC 
received doxorubicin 60 mg/m2 intravenously every 21 days 
for a maximum of 6 cycles plus either sorafenib 400 mg 
orally twice daily or placebo.20 Patients could continue on 
single-agent sorafenib or placebo until disease progression. 
Results of the study showed a longer TTP (8.6 vs 4.8 months) 
and OS (13.7 vs 6.5 months) in favor of the combination 
arm. Response rate was modest in both arms of the 
study (4 vs 2%). Grade 3–4 toxicities were higher in the 
combination arm. A planned intergroup phase II/III study 
to test the doxorubicin and sorafenib combination versus 
sorafenib alone is currently underway.
Safety of sorafenib in patients 
with advanced hepatocellular 
carcinoma
HCC frequently occurs in the setting of chronic liver disease 
and cirrhosis. For this reason a distinction must be made, 
whenever possible, between manifestations of worsening 
chronic liver disease versus drug-related toxicity. Earlier 
clinical trials with sorafenib reported increased bilirubin 
levels in some patients receiving the drug, without other 
evidence to suggest drug-induced liver toxicity.
In the phase I study of sorafenib in patients with advanced 
refractory nonhematological cancers,8 mild diarrhea was the 
most common treatment-related side effect. The maximum 
tolerated dose (MTD) was 400 mg twice daily given 
continuously. Grade 3 or higher dose-limiting toxicities 
were more common in higher doses and comprised diarrhea 
(2 of 6 patients at 800 mg twice daily), fatigue (1 of 6 at 800 mg 
twice daily), and skin toxicity (4 of 14 at 600 mg twice daily). 
In the phase I study of sorafenib in 27 Japanese patients with 
HCC,9 26 out of 27 patients (96.3%) experienced an adverse 
event, the most common being elevated lipase or amylase 
which was transient in the majority (89%) of patients. 
Dermatological events were common (81.5% of patients) as 
were gastrointestinal side effects (70.4%). Dermatological 
events included rash or desquamation in 55% of patients, 
and hand–foot syndrome in 44%. Grade 3 or worse toxicities 
were observed in 23 patients (85.2%), most of which were 
related to laboratory abnormalities. There was no significant 
difference in the incidence and grade of drug-related adverse 
events between the CPA and CPB groups in general, but 
at 400-mg dose level, diarrhea (62.5 vs 33.3%), anorexia 
(50.0 vs 16.7%), hypertension (37.5 vs 16.7%), dry skin 
(37.5 vs 0%), and fatigue (25.0 vs 0%) were more common 
in the CPB patients.
In the phase II study of sorafenib in patients with 
advanced HCC,10 the most common drug-related grade 3 
adverse events were hand–foot syndrome in 5%, fatigue in 
9.5%, and diarrhea in 8 % of patients.The incidence rates 
for all adverse events were similar in CPA (97%) and CPB 
(97%) patients in general. There was no significant difference 
in the incidence and grade of drug-related adverse events 
between the CPA and CPB groups in general including 
fatigue (CPA 41% vs CPB 37%), diarrhea (59 % vs 47%), 
and hand–foot syndrome (30% vs 13%). CPB patients had OncoTargets and Therapy 2009:2 265
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a higher rate of encephalopathy (CPA 2% vs CPB 11%), 
increased bilirubin (18% vs 40%), and worsening ascites 
(CPA 11% vs CPB 18%) when treated with sorafenib.11 
In the HBV-endemic Asian population specific phase II trial,12 
diarrhea was the most common toxicity, occurring in 67% of 
patients, followed by fatigue (55%) and hand–foot syndrome 
(54%). The majority of patients experienced a transient eleva-
tion in AST, ALT, and bilirubin which gradually improved 
after treatment was discontinued.
The most common adverse events reported in the 
phase III SHARP trial for sorafenib13 were predomi-
nantly grade 1 or 2 in severity (Table 2). The overall 
incidence of serious adverse events from any cause was 
similar in both groups (52% vs 54% in the treatment 
and the placebo group respectively). Diarrhea, weight 
loss, hand–foot syndrome, alopecia, anorexia, and voice 
changes occurred at a significantly higher frequency in the 
sorafenib group. Grade 3 drug-related adverse events were 
more common in the sorafenib-treated group and included 
diarrhea (8% vs 2%), hand–foot syndrome (8% vs 1%), 
hypertension (2% vs 1%), and abdominal pain (2% vs 1%) 
in sorafenib and placebo group respectively. Grade 3 or 4 
laboratory abnormalities were similar in both groups except 
grade 3 hypophosphatemia (11% vs 2%) and grade 3 or 4 
thrombocytopenia (4% vs 1%) which were more common 
in the sorafenib group.
Drug discontinuation secondary to toxicity was similar 
in the two study groups (38% vs 37%). The most frequent 
events leading to discontinuation of sorafenib were gas-
trointestinal events (6%), fatigue (5%), and liver dysfunc-
tion (5%). Dose reductions and dose interruptions occurred 
in 26% and 44% of the sorafenib-treated patients versus 7% 
and 30% of patients in the placebo group respectively. Dose 
reduction in the sorafenib group was secondary to diarrhea, 
hand–foot syndrome, and rash or desquamation. Treatment 
was permanently discontinued in 11% of sorafenib-treated 
patients versus 5% of patients treated with placebo group 
secondary to toxicity.
The incidences of serious hepatobiliary adverse events, 
serious hemorrhagic events, variceal bleeding, and renal 
failure (1% and 3%) were similar in both group. Forty-two 
deaths not attributed to disease progression were reported 
within 30 days after the final dose of treatment (13 in the 
sorafenib group vs 29 in the placebo group).
An exploratory subgroup analysis evaluated sorafenib-
related adverse events stratified by HCV status, ECOG 
PS, MVI/EHS, and prior curative treatment. In patients 
with HCV,14 safety profile was similar to the overall study 
population with manageable grade 1–2 toxicity. The most 
common grade 3–4 adverse event in the sorafenib versus 
placebo arm in HCV-positive patients were hand–foot 
syndrome (12.9 vs 0%), diarrhea (10.8 vs 2.4%), hyperbili-
rubinemia (9.7 vs 2.4%), ascites (6.5 vs 9.4%), and fatigue 
(6.5 vs 8.2%). Adverse events led to dose reduction in 32% of 
sorafenib-treated patients versus 8% in the placebo group.
The adverse event profile of sorafenib was also similar 
in patients with PS of 0 compared to PS 1–2. Grade 3–4 
drug-related events were diarrhea (8.8 vs 8.0%), fatigue 
(2.5 vs 5.1%), hand–foot syndrome (8.8 vs 6.6%), hyperten-
sion (1.9 vs 1.5%), and pain (3.1 vs 2.9%) for patients with PS 
0 vs PS 1–2 respectively.15 Patients with or without MVI/ EHS 
treated with sorafenib had similar toxicity profile as well 
Table 2 incidence of drug-related adverse events in phase iii trials of sorafenib in patients with advanced HCC
Toxicities SHARP Asia-Pacific
Sorafenib Placebo Sorafenib Placebo
  Any grade Grade 3–4 Any grade Grade 3–4 Any grade Grade 3–4 Any grade Grade 3–4
HFS 21 8 3 1 45 10 2.7 0
Alopecia 14 0 2 0 25 0 1 0
rash/desquam 16 1 11 0 20 0.7 6.7 0
Fatigue 22 4 16 4 20 3.4 8 1.3
Hypertension 5 2 2 1 19 2 1 0
weight loss 14 1 3 1 13 0 2.7 0
N/v 16 2 11 2 11 0.7 10.7 1.3
Diarrhea 38 8 11 2 25 6 5 0
Liver dysfunc 1 1 0 0 1 0 2.7 0
Bleeding 7 1 4 2 2.7 0 4 0
Abbreviations: N/v, nausea/vomiting; HFS, hand–foot syndrome.OncoTargets and Therapy 2009:2 266
Almhanna and Philip Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
and included diarrhea (5.3 vs 15.7%), hand–foot syndrome 
(6.7 vs 10.1%), and fatigue (4.8 vs 1.1%).16
In the phase III trial of sorafenib in Asia-Pacific patients 
with HCC,18 the most frequently reported adverse events 
(Table 2) were hand–foot syndrome (45% vs 2.7%), 
diarrhea (25% vs 5%), alopecia (25% vs 1.3%), fatigue 
(20% vs 8%), rash or desquamation (20% vs 6.7%), 
hypertension (19% vs 1.3%), and anorexia (13% vs 2.7%). 
Treatment discontinuation due to adverse events was similar 
in both groups (19⋅5% in treatment group and 13⋅3% in the 
placebo group). Dose reductions were needed in 30⋅9% of 
sorafenib-treated compared to 2⋅7% of those treated with 
placebo. Deaths secondary to serious adverse events were 
reported in 70 patients (46 in the sorafenib group and 24 in the 
placebo group). No deaths were considered drug-related.
In the phase II double-blind study of sorafenib plus 
doxorubicin versus placebo plus doxorubicin in patients 
with advanced hepatocellular carcinoma,19 one patient in 
the sorafenib group experienced grade 3–4 left ventricular 
dysfunction. Fatigue and neutropenia were the most 
commonly reported grade 3–4 adverse effects, and they 
occurred equally in both groups of patients.
Conclusion
Sorafenib is a novel drug that targets growth factor receptors 
known to play a role in the pathophysiology of HCC. 
Sorafenib demonstrated antitumor activity as first-line 
therapy in patients with advanced HCC. It demonstrated a 
modest survival benefit over placebo in 2 phase III trials, 
especially in patients with CPA liver disease. Sorafenib has an 
acceptable toxicity profile that includes hand–foot syndrome, 
rash, fatigue, hypertension, and diarrhea.
Given the complexity of the interactions between the 
pathways involved in tumoregensis, targeted therapies with 
different mechanisms of action are being combined in the 
treatment of HCC in order to inhibit numerous pathways. 
Several clinical trials are currently evaluating sorafenib in 
combination with targeted agents in the treatment of HCC; 
these agents include insulin growth factor receptor inhibitor, 
bevacizumab, erlotinib, and angiopoietin 1–2-neutralizing 
peptibody among others. Studies evaluating the combination 
of sorafenib and chemotherapeutic agents are also underway. 
Prognostic and predictive markers need to be developed to 
identify patients with advanced HCC who may or may not 
respond to sorafenib.
Patients with localized disease who have undergone 
resection or liver transplantation are prone to relapse and 
need effective adjuvant therapy. Currently no adjuvant 
therapy is recommended for high-risk patients. Clinical 
trials evaluating the role of sorafenib after, or concurrently 
with, TACE, selective internal radiation (SIR)-spheres, and 
radiation are also underway.
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